Stage III Endometrial Cancer: Analysis of Prognostic Factors and Failure Patterns after Adjuvant Chemotherapy
- 31 October 2001
- journal article
- Published by Elsevier BV in Gynecologic Oncology
- Vol. 83 (1), 1-5
- https://doi.org/10.1006/gyno.2001.6321
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- FIGO Stage IIIC Endometrial Carcinoma with Metastases Confined to Pelvic Lymph Nodes: Analysis of Treatment Outcomes, Prognostic Variables, and Failure Patterns Following Adjuvant Radiation TherapyGynecologic Oncology, 1999
- The Effect of Postsurgical Therapy on Stage III Endometrial CarcinomaGynecologic Oncology, 1996
- New Gynecologic Cancer StagingGynecologic Oncology, 1995
- Postoperative Adjuvant Cisplatin, Doxorubicin, and Cyclophosphamide (PAC) Chemotherapy in Women with High-Risk Endometrial CarcinomaGynecologic Oncology, 1994
- Cisplatin, doxorubicin hydrochloride, and cyclophosphamide followed by radiotherapy in high-risk endometrial carcinomaAmerican Journal of Obstetrics and Gynecology, 1994
- Pathologic stage III endometrial carcinoma. Prognostic factors and patterns of recurrenceCancer, 1993
- The prognostic significance of surgical staging for carcinoma of the endometriumGynecologic Oncology, 1992
- Adjuvant chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (PAC) for early-stage high-risk endometrial cancer: A preliminary analysisGynecologic Oncology, 1990
- Prospective treatment of advanced or recurrent endometrial carcinoma with cisplatin, doxorubicin, and cyclophosphamideGynecologic Oncology, 1990
- Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: A Gynecologic Oncology Group studyGynecologic Oncology, 1990